I've got patience. I spent a whole 8 years on the sideline with this one. And back in 2013 I was a shareholder for less than a week when my stop-loss hit.
Printable View
Very true!
That issue will be overcome when we have patients and more patients using PEB products.
Let's hope Thursday's report gives investors positive news on progress from those KP and LCD developments. If there's been no significant traction then the SP will plummet (again) and any future announcements will be treated with a high degree of skepticism.
On the other hand...
Glad we've had our housing project as a distraction, haven't had time to think about a result either way.
Fingers crossed for all holding tomorrow :)
I hope the number of CMS tests will be at least the same as last year. I also hope there will be some revenue recovery from US (non-CMS and non-KP test) and some more revenue increases from New Zealand. I guess the number of KP tests won't be large according to the latest investor newsletter. And the weaken US dollar would have a substantial impact to the overall revenue.
I bet the revenue will be 8m+
I know of three tests referrals for the CX triage test amongst my social circle within the last month in Christchurch. One was told the test was $200NZ so make sure you get it right ie midstream urine sample. So even if it is not US$900 at least it seems to be getting used.
6 executive team members hired in the past 6 months, all focused on growth. Even if this Ann today isn't great they are hiring by meeting demand at this time or PEB is preparing for what's going to be an accelerated reach in growth this coming months. Either way, the direction of the SP goes today I will hold and if it drops I will be topping up. Good luck all
Highlights:
FLLYR: PEB: PEB Financial Results for the 12 months to 31 March 2021
PACIFIC EDGE FINANCIAL RESULTS FOR THE 12 MONTHS TO 31 MARCH 2021
Pacific Edge reports strong growth momentum despite COVID-19
Summary of performance for the period (% changes compared to prior
comparative period (pcp)):
o Total revenue increased 101% to $10.4m, with operating revenue from test
sales up 76% to $7.7m, despite the negative impact from COVID-19 on test
volumes
o Cash receipts from customers increased 52% on pcp to $6.7m
o Total operating expenses increased 2% on pcp to $24.7m
o Net Loss After Tax improved 25% to $(14.2)m
o Net cash, cash equivalents and short-term deposits increased 56% to $23.1m
as at 31 March 2021
o Operating revenue and cash receipts benefited from reimbursement coverage
by Centers for Medicare and Medicaid Services (CMS) for Cxbladder Detect and
Cxbladder Monitor from 1 July 2020
o Strong performance in 2H21 driven by CMS reimbursement coverage from 1 July
2020 and growing commercial adoption of Cxbladder following a significant
negative impact on test volumes from COVID-19 pandemic in 1H21
o Commercial test use by Kaiser Permanente commenced in late 2020 at a slower
rate than initially expected due to COVID-19 challenges and demands on
physicians; demand is now starting to lift as restrictions ease
o Positive results from the scale-up of US commercial operations starting to
be seen in late Q4 FY21 with record test volumes and U.S. cash receipts
recorded in March 2021
o Positive growth outlook with opportunities being deployed in all target
markets, particularly the U.S.
o Increasing test volumes expected to underpin strong revenue and operating
cashflow growth in FY22 and beyond
Summary of performance for the period (% changes compared to prior comparative period (pcp)):
Total revenue increased 101% to $10.4m, with operating revenue from test sales up 76% to $7.7m, despite the negative impact from COVID-19 on test volumes
Cash receipts from customers increased 52% on pcp to $6.7m
Total operating expenses increased 2% on pcp to $24.7m
Net Loss After Tax improved 25% to $(14.2)m
Net cash, cash equivalents and short-term deposits increased 56% to $23.1m as at 31 March 2021
Operating revenue and cash receipts benefited from reimbursement coverage by Centers for Medicare and Medicaid Services (CMS) for Cxbladder Detect and Cxbladder Monitor from 1 July 2020
Strong performance in 2H21 driven by CMS reimbursement coverage from 1 July 2020 and growing commercial adoption of Cxbladder following a significant negative impact on test volumes from COVID-19 pandemic in 1H21
Commercial test use by Kaiser Permanente commenced in late 2020 at a slower rate than initially expected due to COVID-19 challenges and demands on physicians; demand is now starting to lift as restrictions ease
Positive results from the scale-up of US commercial operations starting to be seen in late Q4 FY21 with record test volumes and U.S. cash receipts recorded in March 2021
Positive growth outlook with opportunities being deployed in all target markets, particularly the U.S.
Increasing test volumes expected to underpin strong revenue and operating cashflow growth in FY22 and beyond
Is todays report available to view live today? Cheers
Test throughput is the same so revenue uplift is literally because they are now being paid for the tests... Though no doubt there is definitely a rather large momentum shift in play
Some 25% of the 10m revenue from grants and covid support ....thats good
Cash burn pretty hefty
But things going to plan ....great future.
Pay attention to Note 5 from the financial statements. It provides very useful insight of the revenue regonition and source. It also provide some info about 'medically necessary' and 'Medicare Adcantage'.
Dub dubs.....
The potentials of this business are so high, all the gears are in places, now just.. VROOM...VROOM...VROOM...
This business is a gold mine to invest for the future.